Keith Wheatley

Q: What Schools Are Affiliated With Keith Wheatley

Keith Wheatley is affiliated with the following schools: University of California, Berkeley, Paris-Saclay University, University of Oxford, Newcastle University, University of Wales, Stanford University, University of Birmingham, University of Cambridge

Keith Wheatley's AcademicInfluence.com Rankings

Keith Wheatley

Computer Science

#6591

World Rank

#6949

Historical Rank

Computational Linguistics

#1171

World Rank

#1185

Historical Rank

Machine Learning

#2194

World Rank

#2222

Historical Rank

Artificial Intelligence

#2461

World Rank

#2502

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Keith Wheatley's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Keith Wheatley Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Keith Wheatley's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. (1998) (2740)
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003) (2143)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. (2010) (1676)
Mortality in relation to smoking: 40 years' observations on male British doctors (1994) (1491)
Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors (1994) (1221)
Randomised trial of prophylactic daily aspirin in British male doctors (1988) (1160)
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. (2001) (927)
Association between premature mortality and hypopituitarism (2001) (876)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. (2005) (814)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study (2005) (679)
Revascularization versus medical therapy for renal-artery stenosis. (2009) (647)
Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial (2010) (646)
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. (2011) (596)
Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial (1998) (577)
A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment (2007) (573)
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. (1998) (520)
Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. (2001) (459)
A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial (1999) (444)
Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. (1999) (424)
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. (2001) (424)
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. (2008) (402)
Physiotherapy versus placebo or no intervention in Parkinson's disease. (2012) (371)
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. (2012) (369)
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. (2007) (349)
The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial (2002) (338)
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. (2003) (333)
Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. (1997) (329)
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. (2009) (325)
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. (2013) (316)
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. (2007) (310)
Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials (1999) (295)
Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials (2005) (289)
Physiotherapy intervention in Parkinson’s disease: systematic review and meta-analysis (2012) (279)
Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. (2010) (275)
Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. (2007) (270)
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial (1998) (266)
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. (2005) (256)
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. (2008) (253)
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials (2009) (233)
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. (2005) (231)
Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. (1997) (222)
Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial (2013) (222)
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. (2014) (220)
Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. (2004) (216)
Dopamine agonist therapy in early Parkinson's disease. (2008) (213)
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. (2010) (211)
Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors (2017) (190)
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. (2005) (189)
Physiotherapy for Parkinson's disease: a comparison of techniques. (2014) (180)
Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. (2012) (176)
Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial (2011) (175)
Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. (2013) (167)
Guidelines on the management of acute myeloid leukaemia in adults (2006) (157)
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison (2013) (153)
How to avoid bias when comparing bone marrow transplantation with chemotherapy. (1991) (152)
Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials. (2003) (150)
Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials (2003) (149)
Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients (2004) (145)
Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. (2001) (140)
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial (2009) (139)
Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials (2007) (138)
AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial (1989) (137)
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. (1998) (135)
A randomised controlled trial of treatment for idiopathic intracranial hypertension (2011) (134)
Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. (2014) (134)
Bisphosphonates in multiple myeloma: a network meta-analysis. (2012) (133)
Establishing the presence of the t( 15; 17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial (1996) (133)
Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol (2010) (132)
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. (2013) (130)
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. (2006) (130)
Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis. (2017) (128)
Physiotherapy versus placebo or no intervention in Parkinson's disease. (2013) (126)
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. (2009) (121)
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. (2004) (120)
Treatment‐related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council Acute Myeloid Leukaemia Trial (MRC AML10) (1999) (119)
Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone (1999) (119)
A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia (1998) (119)
Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial (1999) (118)
A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. (2014) (115)
Bisphosphonates in multiple myeloma. (2001) (113)
Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial (2009) (111)
Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials (1997) (108)
Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. (2010) (106)
Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party (2002) (105)
Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. (1995) (101)
Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative (2015) (101)
Treatment for myeloid leukaemia of Down syndrome: population‐based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials (2006) (101)
Bisphosphonates in multiple myeloma. (2002) (101)
Dose intensification in acute myloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's ATML9 study (1996) (101)
Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials (2010) (97)
High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. (2018) (97)
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease: A Randomized Double-Blind Trial (2018) (94)
Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial. (2004) (92)
Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trial (2001) (92)
Frequency of CBFβ/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials (1997) (88)
Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). (1996) (86)
The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial. (2006) (84)
Calcineurin Inhibitor Sparing With Mycophenolate in Kidney Transplantation: A Systematic Review and Meta-Analysis (2009) (83)
Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease (2011) (81)
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. (2020) (79)
Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. (2016) (78)
Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. (2004) (78)
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. (2010) (77)
Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization. (2003) (76)
Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy – Results of a United Kingdom phase II trial (CNS 2007 04)☆ (2013) (75)
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial (2013) (75)
Physiotherapy and Occupational Therapy vs No Therapy in Mild to Moderate Parkinson Disease: A Randomized Clinical Trial. (2016) (70)
Patterns of care and survival for adolescents and young adults with acute leukaemia – a population-based study (1999) (70)
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature (2017) (68)
Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy (2018) (63)
Understanding meta-analysis (2001) (62)
Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomised controlled trial (PD REHAB). (2016) (62)
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML (2012) (59)
Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia (2014) (59)
High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. (2019) (56)
Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation. (2016) (55)
EVI1 expression in acute myeloid leukaemia (2001) (53)
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. (2016) (52)
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia (2020) (50)
Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? – A statistician's view (2002) (49)
An occupational therapy intervention for residents with stroke related disabilities in UK care homes (OTCH): cluster randomised controlled trial (2015) (47)
Early versus deferred treatment for early stage multiple myeloma. (2003) (46)
Improved outcome of acute myeloid leukaemia in Down’s syndrome (1999) (46)
Randomized placebo‐controlled trial of granulocyte colony stimulating factor (G‐CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party (2009) (45)
Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990–99 (2002) (44)
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol (2019) (44)
Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation (2019) (44)
Evaluating drug treatments for Parkinson's disease: how good are the trials? (2002) (43)
Pilot randomised controlled trial of occupational therapy to optimise independence in Parkinson's disease: the PD OT trial (2008) (41)
Del (9q) AML: clinical and cytological characteristics and prognostic implications (2005) (41)
Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial. (2007) (41)
WARP - A multicentre prospective randomised controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs) (2005) (40)
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features (2018) (39)
The Addition of Arsenic Trioxide to Low Dose Ara-C in Older Patients with AML Does Not Improve Outcome (2011) (35)
Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data (2016) (35)
Alcohol and coronary heart disease reduction among British doctors: confounding or causality? (1997) (34)
The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial (2011) (34)
Relationship between FLT 3 mutation status , biologic characteristics , and response to targeted therapy in acute promyelocytic leukemia (2005) (33)
Large-scale randomized evidence: trials and overviews. (2008) (33)
VITATOPS, the VITAmins TO Prevent Stroke Trial: Rationale and Design of a Randomised Trial of B-Vitamin Therapy in Patients with Recent Transient Ischaemic Attack or Stroke (NCT00097669) (ISRCTN74743444) (2007) (32)
Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). (2020) (32)
Does adjuvant vaccine therapy really have activity in malignant melanoma? (2007) (32)
Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia (1999) (32)
Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial. (2009) (31)
Home-based reach-to-grasp training for people after stroke: study protocol for a feasibility randomized controlled trial (2013) (31)
Bortezomib for the treatment of multiple myeloma. (2016) (31)
Bisphosphonates in multiple myeloma. (2010) (31)
THE RETINOBLASTOMA GENE (RB1) IN ACUTE MYELOID LEUKAEMIA: ANALYSIS OF GENE REARRANGEMENTS, PROTEIN EXPRESSION AND COMPARISON OF DISEASE OUTCOME (1996) (30)
Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012). (2020) (30)
What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML Trial (1997) (29)
A modular questionnaire for the assessment of longterm quality of life in leukaemia patients: The MRC/EORTC QLQ-LEU (1996) (28)
Fludarabine, cytosine arabinoside, granulocyte‐colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes (2004) (27)
Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops? (2011) (27)
Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease (PD COMM pilot): study protocol for a randomized controlled trial (2014) (27)
Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC Adult Leukaemia Working Party. (1997) (26)
Cost‐utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trial (2016) (25)
Impact of karyotype on treatment outcome in acute myeloid leukemia. (2004) (25)
Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT‐1 study (2017) (25)
Surgery for Parkinson’s disease: lack of reliable clinical trial evidence (2003) (24)
Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease: a pilot randomised controlled trial (PD COMM pilot) (2018) (24)
UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma. (2016) (23)
A Sensitive Risk Score for Directing Treatment in Younger Patients with AML. (2006) (23)
Prognostic importance of Sudan Black positivity: a study of bone marrow slides from 1386 patients with de novo acute myeloid leukaemia (1991) (23)
Low Dose Ara-C Versus Hydroxyurea with or without Retinoid in Older Patients Not Considered Fit for Intensive Chemotherapy: The UK NCRI AML14 Trial. (2004) (23)
Adjuvant interferon-alpha in malignant melanoma: current status. (2000) (23)
Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul). (2016) (22)
An Occupational Therapy intervention for residents with stroke-related disabilities in UK Care Homes (OTCH): cluster randomised controlled trial with economic evaluation. (2016) (22)
SAB – a promising new treatment to improve remission rates in AML in the elderly? (2002) (21)
Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. (2019) (20)
PEPtalk: postexposure prophylaxis against varicella in children with cancer (2011) (20)
A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma (2020) (20)
Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): An individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts). (2014) (19)
Comparing results from long and short form versions of the Parkinson's disease questionnaire in a longitudinal study. (2015) (18)
A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom medical research council (MRC) AML10 trial. (1995) (18)
The Medical Research Council PT1 Trial in Essential Thrombocythemia. (2004) (17)
Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment prediction (2009) (17)
Haematologists' approaches to the management of adolescents and young adults with acute leukaemia (2000) (17)
Comparison of anticipated and actual control group outcomes in randomised trials in paediatric oncology provides evidence that historically controlled studies are biased in favour of the novel treatment (2011) (16)
Long-term results of the MRC AML10 trial. (2006) (16)
A cluster randomised controlled trial of an occupational therapy intervention for residents with stroke living in UK care homes (OTCH): study protocol (2012) (16)
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. (2015) (16)
Randomized phase 2 trial of the combination of vincristine and irinotecan with or without temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS). (2019) (16)
Home-based Reach-to-Grasp training for people after stroke is feasible: a pilot randomised controlled trial (2017) (16)
Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial (EE99R2Loc). (2016) (15)
Interferon as adjuvant treatment for melanoma (2002) (14)
UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria (2016) (14)
PEPtalk2: results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer (2018) (14)
Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue (2018) (14)
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY) (2020) (13)
Results of Inter-B-NHL Ritux 2010 - Phase II Study of DA-EPOCH-R for Children and Adolescents with Primary Mediastinal Large B-Cell Lymphoma (PMLBL) on Behalf of European Intergroup for Childhood Non Hodgkin's Lymphoma (EICNHL) and Children's Oncology Group (COG) (2017) (13)
Intensity-modulated arc therapy to improve radiation dose delivery in the treatment of abdominal neuroblastoma. (2013) (13)
Longer-term efficiency and safety of increasing the frequency of whole blood donation (INTERVAL): extension study of a randomised trial of 20 757 blood donors (2019) (13)
Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations (2011) (12)
RESULTS OF a PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY) (2017) (12)
Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT. (2019) (12)
REFINEMENT OF CYTOGENETIC CLASSIFICATION IN AML: DETERMINATION OF PROGNOSTIC SIGNIFICANCE OF RARE RECURRING CHROMOSOMAL ABNORMALITIES AMONGST 5635 YOUNGER ADULTS TREATED IN THE UK MRC TRIALS (2009) (12)
Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial. (1996) (11)
FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research—a systematic review and meta-analysis (2020) (11)
A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma - BEACON-Neuroblastoma, a European Innovative Therapies for Children with Cancer (ITCC) - International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN (2015) (11)
Randomized comparison of VAC versus VAI chemotherapy (CT) as consolidation for standard risk (SR) Ewing sarcoma tumor (ES): Results of the Euro-EWING.99-R1 trial. (2011) (10)
Hyperfractionated Accelerated Radiotherapy (HART) with maintenance chemotherapy for metastatic (M1-3) Medulloblastoma--a safety/feasibility study. (2014) (10)
Systematic review and meta-analysis of hydrocarbon exposure and the risk of Parkinson's disease. (2015) (10)
Allo and auto BMT reduce relapse risk in AML in CR1 but do not significantly improve overall survival Results of the MRC AML 10 trial (1996) (10)
Lack of benefit of G-CSF on complete remission and possible increased relapse risk in AML: An MRC study of 800 patients [Abstract] (1997) (10)
The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial. (1999) (10)
Priority-setting decisions for new cancer drugs (2002) (10)
Rating the intelligibility of dysarthic speech amongst people with Parkinson’s Disease: a comparison of trained and untrained listeners (2019) (10)
Clinical Significance of MPL Mutations in Essential Thrombocythemia: Analysis of the PT-1 Cohort. (2007) (10)
British Society for Skin Care in Immunosuppressed Individuals (2020) (10)
Human gastric perfusion: Evidence for non‐uniformity of blood flow (1988) (9)
Response: Still a need for more robust evidence that FLT3/ITD status should influence the decision to proceed to transplantation in AML patients (2007) (9)
Effect of renal artery revascularization upon cardiac structure and function in atherosclerotic renal artery stenosis: cardiac magnetic resonance sub-study of the ASTRAL trial (2016) (9)
Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial (2021) (9)
Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial (2021) (9)
The paediatric hepatic international tumour trial (PHITT): clinical trial design in rare disease (2015) (9)
The effectiveness and safety of proton beam radiation therapy in children with malignant central nervous system (CNS) tumours: protocol for a systematic review (2016) (9)
The impact of transplant in AML in 2nd CR: A prospective study of 741 in the MRC AML 10 and 12 Trials [Abstract] (2004) (8)
Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers (2019) (8)
The utility of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with low-grade central nervous system (CNS) tumours: a systematic review (2018) (8)
The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison (2010) (8)
JAK2 V617F Mutation Identifies a Biologically Distinct Subtype of Essential Thrombocythemia Which Resembles Polycythemia Vera. (2005) (8)
Favourable prognosis associated with FLT3 tyrosine kinase domain mutations in AML in contrast to the adverse outcome associated with internal tandem duplications [Abstract] (2005) (8)
Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: progress report on the MRC AML 10 trial. Medical Research Council Working Party on Childhood Leukaemia. (1992) (7)
The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials. (2000) (7)
Aspirin use and chronic diseases (1990) (7)
Physiotherapy versus placebo or no intervention in Parkinson's disease. (2012) (7)
The relationship between FLT3 mutation status: biological characteristics and outcome in patients with acute promyelocytic leukaemia. (2003) (6)
Attempts to modulate chemoresistance in older patients with AML using PSC-833 - Results of the LRF AML14 trial (2003) (6)
Modification or Dose or Treatment Duration Has No Impact on Outcome of AML in Older Patients: Preliminary Results of the UK NCRI AML14 Trial. (2005) (6)
The significance of ultrastructural features in acute myeloid leukemia: a study of 220 patients entered into the Medical Research Council's ninth acute myeloid leukemia trial. (1989) (6)
Need for a quantitative meta-analysis of trials of adjuvant interferon in melanoma. (2002) (6)
Corner cutting compromises clinical trials: the inherent problems with up-front randomisation and a common standard arm. (2003) (5)
Cost‐Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease (2021) (5)
Refinement of cytogenetic classification in AML: determination of prognostic significance of rare recurring chromosomal abnormalities amongst patients entered into the UK MRC AML 10 & 12 trials. (2002) (5)
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments) (2022) (5)
Does all-transretinoic acid (ATRA) have a role in non-APL acute myeloid leukaemia?: Results from 1666 patients in three MRC trials [Abstract] (2004) (5)
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy (2021) (5)
Meta-analyses of randomised controlled trials (RCT) of warfarin and low molecular weight heparin (LMWH) for the prevention of venous thromboembolism (VTE) and death in cancer patients (2005) (5)
Outcome of acute myeloid leukaemias affecting core binding factor subunits: the UK MRC experience (1997) (4)
Reply to J. Thiele et al (2009) (4)
Prognostic factors in older AML patients receiving intensive and non-intensive therapy: Analysis of the UK AML11 and AML14 trials [Abstract] (2005) (4)
1.091 A LARGE RANDOMISED TRIAL ASSESSING QUALITY OF LIFE IN PATIENTS WITH EARLY PD: RESULTS FROM PD MED EARLY (2012) (4)
Varicella postexposure prophylaxis in children with cancer: urgent need for a randomised controlled trial (2012) (4)
Should Stem Cell Transplantation (SCT) Be Recommended for Any Child with AML in 1st CR (2005) (4)
Inappropriate reporting and interpretation of subgroups in the AML-BFM 93 study (2001) (4)
MOLECULAR PREDICTORS OF RESPONSE TO AZACITIDINE THERAPY: THE RESULTS OF THE UK TRIALS ACCELERATION PROGRAMME RAVVA STUDY (2017) (4)
The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial (2008) (4)
Relationships between age at diagnosis, clinical features and outcome of therapy in children treated in the Medical Research Council trials for acute myeloid leukemia AML 10 and 12. (2000) (4)
Consolidation of AML therapy with autograft and allograft procedures does not negate the poor prognostic impact of FLT3 internal tandem duplications: Results from the UK MRC AML 10 and 12 trials. (2002) (4)
Low dose Ara-C versus low Dose Ara-C and Tipifarnib: result of the UK NCRI AML16 "Pick a Winner" comparison [Abstract] (2008) (4)
Del(9q) AML: Clinical, cytological and cytogenetic characteristics and prognostic implications for patients entering the MRC AML trials. (1999) (4)
Evaluation of Prospective Detection of PML-RARA and RARA-PML Fusion Transcripts by Real-Time Quantitative PCR (RQ-PCR) To Direct Pre-Emptive Therapy with Arsenic Trioxide (ATO) in Acute Promyelocytic Leukemia (APL) Patients Treated in the UK MRC AML15 Trial. (2007) (4)
Comparative Effectiveness of Bisphoshonates In Multiple Myeloma (2010) (4)
Adjuvant interferon for melanoma. (2002) (4)
Cytogenetics of childhood AML from UK medical research council treatment trials, AML10 & 12. (2003) (4)
Treatment Reasons, Resource use and Costs of Hospitalisations in People with Parkinson's: Results from a Large Rct. (2014) (3)
Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk neuroblastoma (RR-HRNB): Results of the BEACON-Neuroblastoma randomized phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC) - International Society of Pediatric Oncology Europe N (2019) (3)
Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial (2016) (3)
ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit (2003) (3)
The impact of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis (2016) (3)
A cluster randomised controlled trial of an occupational therapy intervention for residents with stroke living in UK care-homes (2013) (3)
Home-based reach-to-grasp training for people after stroke: a feasibility randomised controlled trial (2015) (3)
Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed or refractory high-risk neuroblastoma (RR-HRNB): First survival results of the ITCC-SIOPEN BEACON-Neuroblastoma phase II trial. (2020) (3)
DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) (2012) (3)
Hydroxycarbamide Plus Aspirin Vs Aspirin Alone in Intermediate Risk Essential Thrombocythemia: Results of the PT-1 International, Prospective, Randomized Clinical Trial (2017) (3)
Predictive value of Minimal Residual Disease (MRD) monitoring by RQ-PCR in WT1 positive patients entered in the UK MRC AML-15 trial (2008) (3)
Problems with up-front randomization in clinical trials. (2006) (3)
Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial (2021) (3)
Riluzole for motor neurone disease. Large, more economical trial is needed. (2001) (3)
The role of molecular diagnosis & residual disease monitoring in APL: Results of the MRC ATRA trial (1998) (3)
Adjuvant interferon therapy for melanoma. (2005) (3)
Daunorubicin and Cytarabine Compared with Daunorubicin, Cytarabine and the MDR1 Reversal Agent PSC-833 in Elderly Patients with Acute Myelogenous Leukemia. (2004) (2)
Molecular characterisation of patients with APL entered into the UK MRC ATRA trial: Relationship of PML breakpoint with additional cytogenetic abnormalities and outcome [Abstract] (1997) (2)
Cabergoline versus levodopa monotherapy (2004) (2)
Bevacizumab for children with relapsed & refractory high-risk neuroblastoma (RR-HRNB): Results of the BEACON-neuroblastoma randomized phase II trial - A European ITCC-SIOPEN trial (2019) (2)
The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial (2019) (2)
The role of high-dose myeloablative chemotherapy with haematopoietic stem cell transplantation (HSCT) in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis (2015) (2)
BEACON-Immuno: Results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC–International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial. (2022) (2)
tandem duplications in patients with acute myeloid leukemia and have a significantly more favorable prognosis than FLT3 internal FLT3 tyrosine kinase domain mutations are biologically distinct from (2013) (2)
Stem Cell Transplants in Acute Myeloid Leukaemia (AML) (1998) (2)
Aim high - Adjuvant interferon in melanoma (high risk): No confirmation yet that low dose interferon is of benefit (2001) (2)
High-dose chemotherapy and stem cell transplantation does not improve relapse-free or overall survival in women with high-risk breast cancer. (2004) (2)
Cardiac structure and function after revascularization versus medical therapy for renal artery stenosis: the ASTRAL heart echocardiographic sub-study (2019) (2)
The utility of routine surveillance screening with magnetic resonance imaging to detect tumor recurrence/progression in children with high‐grade central nervous system tumors: a systematic review (2018) (2)
Low dose Ara-C versus low dose Ara-C and arsenic trioxide: The UK NCRI AML16 "Pick a Winner" comparison [Abstract] (2009) (2)
DESIGN OF THE MYECHILD TRIAL, AN INTERNATIONAL RANDOMISED PHASE III CLINICAL TRIAL IN CHILDREN WITH ACUTE MYELOID LEUKAEMIA INCORPORATING AN EMBEDDED DOSE FINDING STUDY (2015) (2)
Using systematic reviews to identify research gaps - a case study: mIBG for the treatment of neuroblastoma in children (2013) (2)
Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT. (2022) (2)
Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myelogenous Leukemia: To Transplant or Not to Transplant? A Systematic Review of International Guidelines. (2009) (2)
Flexible trial design in a rare condition (2013) (1)
Impact of gender on efficacy and acute toxicity in standard risk localized (SR) Ewing sarcomas (ES) in the Euro-Ewing99-R1 trial. (2013) (1)
The Role of BMT in AML in Relation to Prognostic Characteristics (1998) (1)
Long-term tapering versus standard prednisolone therapy for the treatment of the initial episode of childhood nephrotic syndrome: national multicentre double-blind phase III randomised controlled trial and economic evaluation (2019) (1)
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial (2022) (1)
Children's Liver Tumour European Research Network, ChiLTERN, H2020 (2018) (1)
Outcome of reduced intensity allografts in patients aged over 45 years with Acute Myeloid Leukaemia: initial results of the MRC AML15 trial (2009) (1)
Response: Allogeneic stem cell transplantation and FLT3/ITD status in AML (2006) (1)
A duplication cyst masquerading as a meckel's diverticulum (2012) (1)
hTERT expression in AML is heterogeneous and is of likely prognostic significance (2006) (1)
1089PDRELAPSE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADJUVANT INTERFERON TRIALS IN PATIENTS (PTS) WITH RESECTABLE CUTANEOUS MELANOMA: AN INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS. (2014) (1)
Correlation of response with progression-free (PFS) and overall (OS) survival in relapsed/refractory Ewing sarcoma (RR-ES): Results from the rEECur trial. (2020) (1)
Bisphosphonates in Multiple Myeloma. A Systematic Review and Meta Analysis. (2009) (1)
The presence of the factor V Leiden and the prothrombin G20210A polymorphism does not appear to influence the risk of thrombosis in essential thrombocythaernia: results of a nested case control study (2008) (1)
PD REHAB: a large pragmatic randomised controlled trial of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease (2014) (1)
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial. (2023) (1)
Randomised trial of prophylactic daily aspirin in British male doctors: Authors' reply (1988) (1)
Clinical trials in rare diseases: a review of practice (2013) (1)
Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting (2022) (1)
Strategies for New Agent Development and Clinical Trial Considerations (2011) (1)
Abstract PO010: Molecular characterization of pediatric hepatocellular carcinoma: genomic, methylomic and transcriptomic analysis (2022) (0)
How Should We Prevent Hematologic Relapse of Acute Promyelocytic Leukemia? Reply (2010) (0)
Impact of Platelet Glycoprotein Polymorphisms upon Clinical Events in Essential Thrombocythaemia Patients Enrolled in the PT1 Trial. (2007) (0)
The Use of Apomorphine in the PD SURG Trial (2010) (0)
Meta-analysis of selegiline trials in early Parkinson's disease (2004) (0)
University The role of high-dose myeloablative chemotherapy with haematopoietic stem cell transplantation (HSCT) in children with central nervous system (CNS) tumours (2015) (0)
Occupational therapy initial interview log (2016) (0)
Functional p-glycoprotein and internal tandem duplications of FLT3 are characteristic of discrete populations of elderly AML patients. (2005) (0)
DIFFUSE INTRINSIC PONTINE GLIOMA TREATED WITH PROLONGED TEMOZOLOMIDE AND RADIOTHERAPY - RESULTS OF THE UNITED KINGDOM TRIAL (CNS 2007 04) (2012) (0)
Impact of Marrow Transplantation in Acute Myeloid Leukemia in First Complete Remission: Experience from MRC AML-10 Trial (1997) (0)
Bortezomib for the treatment of multiple myeloma: A systematic review and meta-analysis (2015) (0)
Consultee declaration form (2016) (0)
High-dose chemotherapy and autologous stem cell transplantation for multiple myeloma (2003) (0)
Aspirin use and chronic diseases (III) (1990) (0)
Adverse event/serious adverse event form (2016) (0)
Trial Sequential Analysis in Meta-Analyses of Maintenance Therapies for Multiple Myeloma. (2012) (0)
Summary of participants moving home during the course of the trial (2016) (0)
Occupational therapy information leaflet (2016) (0)
Data tables for Figures 2 and 3 (2016) (0)
European Quality of Life-5 Dimensions, 3 Levels health profile (2016) (0)
Meta-analysis of randomised comparisons between the effects of warfarin and low molecular weight heparin in thromboprophylaxis and mortality in cancer patients [Abstract] (2007) (0)
AML in Children: The Medical Research Council Data (2001) (0)
University of Birmingham Interleukin-2 receptor monoclonal antibodies in renal transplantation (2003) (0)
Information for occupational therapists delivering interventions for Occupational Therapy intervention for residents with stroke living in UK Care Homes trial (2016) (0)
Expression of Nm23-H1 in AML correlates with white cell count at diagnosis and in vitro acts as a survival factor for primary AMLs cells; evidence of a novel autocrine survival factor in AML. (2003) (0)
myeloid leukemia following chemotherapy Genetic variation in XPD predicts treatment outcome and risk of acute (2013) (0)
Maintenance therapies for multiple myeloma (2016) (0)
HG-54THE ROLE OF HIGH-DOSE MYELOABLATIVE CHEMOTHERAPY (HDCT) WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHILDREN WITH HIGH GRADE GLIOMAS (HGG) OR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): RESULTS OF A SYSTEMATIC REVIEW (2016) (0)
Preliminary results of a phase II study of brentuximab vedotin using a response adapted design for the first line treatment of patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (BREVITY) (2016) (0)
INVESTIGATING THE HETEROGENEITY OF ALKYLATING AGENTS' EFFICACY AND TOXICITY BETWEEN GENDERS: A META-ANALYSIS OF RANDOMIZED TRIALS COMPARING CYCLOPHOSPHAMIDE AND IFOSFAMIDE (MAIAGE STUDY) (2015) (0)
Does stimulus predict the best candidates for deep brain stimulation for PD? (2013) (0)
P1.158 Incidence and predictors of dementia in the PD MED trial (2009) (0)
RO-08THE EFFECTIVENESS AND SAFETY OF PBT IN CHILDREN WITH MALIGNANT CENTRAL NERVOUS SYSTEM (CNS) TUMOURS: A SYSTEMATIC REVIEW. (2016) (0)
High-dose chemotherapy for breast cancer (2003) (0)
Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study (2019) (0)
Classification of Philadelphia Translocation-Negative Myeloproliferative Neoplasms: Its Impact on Data From Clinical Trials Reply (2009) (0)
Trial exit form (2016) (0)
General practitioner letter (2016) (0)
P-Glycoprotein Overexpresion and Internal Tandem Duplications of FLT3 Are Characteristic of Discrete Populations of Elderly AML Patients. (2004) (0)
First‐line double high‐dose chemotherapy and autologous stem cell transplantation versus single high‐dose chemotherapy and autologous stem cell transplantation in multiple myeloma (2008) (0)
randomized trial G-CSF and ATRA are not beneficial: results of the MRC AML-HR chemotherapy in high-risk acute myeloid leukemia, and addition of Fludarabine and cytosine are less effective than standard ADE (2013) (0)
Patient invitation letter (2016) (0)
P2.139 Incidence and predictors of motor complications in the PD MED trial (2009) (0)
Retinoic Acid: Result of the Randomized MRC Trial All-Trans Predict Prognosis in Acute Promyelocytic Leukemia Treated With Presenting White Blood Cell Count and Kinetics of Molecular Remission (2013) (0)
Occupational Therapy intervention for residents with stroke living in UK Care Homes training workbook (2016) (0)
The addition of gemtuzumab ozogamicin to induction chemotherapy in AML reduces relapse and improves survival in the majority of patients of all ages: the AML15 and 16 trial experience [Abstract] (2012) (0)
Occupational Therapy intervention for residents with stroke living in UK Care Homes health-care resource usage questionnaire: 12 months (2016) (0)
PND41 Parkinson's Disease Questionnaire (PDQ-39) As a Primary Endpoint in a Trial Comparing Deep Brain Stimulation With Best Medical Therapy Versus Best Medical Therapy Alone for Advanced Parkinson's Disease (PD SURG TRIAL): A Randomised, Open-Label Trial (2012) (0)
P2.125 Parkinson's disease treatments in practice: evidence from the PD MED trial (2009) (0)
MB-55THE ROLE OF HIGH-DOSE MYELOABLATIVE CHEMOTHERAPY (HDCT) WITH AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHILDREN WITH MEDULLOBLASTOMA: RESULTS OF A SYSTEMATIC REVIEW. (2016) (0)
Demographic front sheet (2016) (0)
Maintenance Therapies for Multiple Myeloma (MM): A Direct Meta-Analysis (2012) (0)
a copy of The impact of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with central system (CNS) tumours : Protocol for a systematic review and meta-analysis (2019) (0)
Voice Treatment versus standard speech and language therapy versus control in Parkinson ’ s disease : (2018) (0)
Oral Presentations (2002) (0)
PD REHAB RCT OF PHYSIOTHERAPY AND OT IN PARKINSON'S DISEASE (2014) (0)
1102 POSTER Meta-analysis of randomised comparisons between the effects of warfarin and low molecular weight heparin in thromboprophylaxis and mortality in cancer patients (2007) (0)
University of Birmingham The utility of routine surveillance screening with magnetic resonance imaging to detect tumour recurrence/progression in children with high-grade central nervous system tumours (2018) (0)
Role of entacapone in later Parkinson's disease not yet established. (2004) (0)
General practitioner’s letter requesting confirmation of participant eligibility (2016) (0)
AT-12THE ROLE OF HIGH-DOSE MYELOABLATIVE CHEMOTHERAPY (HDCT) WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHILDREN WITH ATYPICAL TERATOID RHABDOID TUMOURS (AT/RT): RESULTS OF A SYSTEMATIC REVIEW (2016) (0)
Investigating the heterogeneity of alkylating agents’ efficacy between genders: A meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study). (2015) (0)
P2.049 Beneflts and risks of deep brain stimulation (DBS) for Parkinson's disease (PD) – results from the PD SURG study (2009) (0)
Consultee information sheet (2016) (0)
Reply to S. Nagai et al (2010) (0)
Health-care usage questionnaire (2016) (0)
Adjuvant interferon in high risk mealnoma, the AIM High study (2003) (0)
Changes in physician prescribing patterns over time in the PD MED trial (2009) (0)
Adverse events reporting form (2016) (0)
PROGNOSTIC IMPORTANCE OF MYELOPEROXIDASE POSITIVITY IN DENOVO ACUTE MYELOID-LEUKEMIA (1992) (0)
NGS IDENTIFIES MUTATIONS PROGNOSTIC OF RELAPSE AFTER ALLO-SCT AND NOVEL CLONE EMERGENCE AT DISEASE RECURRENCE: IMPLICATIONS FOR STRATEGIES TO PREVENT POST ALLO-SCT RELAPSE (2016) (0)
Molecular and cytogenetic assessment of patients with acute promyelocytic leukaemia (APL) entered into the UK MRC ATRA trial [Abstract] (1995) (0)
Evaluation of prospective real-time quantitative PCR monitoring for minimal residual disease to predict relapse and direct molecularly targeted therapy with arsenic trioxide in acute promyelocytic leukaemia: analysis of 407 patients, including results of the MRC AML15 trial [Abstract] (2008) (0)
Maintenance Therapies for Multiple Myeloma (MM): A Network Meta-Analysis (2012) (0)
Does ‘mapping’ the evidence usefully inform the research question prioritisation process in systematic reviews? (2015) (0)
Occupational therapy treatment record form (2016) (0)
The favourable prognostic impact of tyrosine kinase domain mutations of FLT3 in AML is related to the level of mutation (2006) (0)
Intensified Dosing of Gemtuzumab Ozogamicin Can be Safely Combined with Induction Chemotherapy in Children with Acute Myeloid Leukaemia (AML) and High Risk Myelodysplasia (MDS) (2018) (0)
Bone Marrow Fibrosis and Diagnosis of Essential Thrombocythemia Reply to J. Thiele et al (2009) (0)
University of Cost-effectiveness of dopamine agonists and monoamine oxidase B inhibitors in early Parkinson's disease (2021) (0)
NM23-H1 acts as a potent survival factor against primary AML cells and normal blast cells [Abstract] (2005) (0)
Flow diagram of randomisation process (2016) (0)
Evaluation of Stem Cell Transplantation in AML (1998) (0)
Initial participant interview (2016) (0)
P2.140 Meta-analysis of DBS surgery in patients with advanced Parkinson's disease (2009) (0)
Physiotherapy treatment record form (2016) (0)
Abstract PO011: Proteomic profiling of childhood liver cancer: identification of novel diagnostic and prognostic biomarkers (2022) (0)
1413 The Paediatric Hepatic International Tumour Trial (PHITT) design (2015) (0)
PO-60 Meta-analysis of randomised comparisons between the effects of warfarin and low molecular weight heparin in thromboprophylaxis and mortality in cancer patients (2007) (0)
Comparison of anticipated and actual control group outcome in randomised trials in paediatric oncology provides evidence that non-randomised studies are biased in favour of the novel treatment (2011) (0)
1402 Design of the Myechild trial, an international randomised phase III clinical trial in children with acute myeloid leukaemia incorporating an embedded dose finding study (2015) (0)
Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04) (2022) (0)
Reply to response to Wheatley et al., "Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation" Cancer Treatment Reviews April 2016;45:76. (2017) (0)
Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity (2016) (0)
Re: Interleukin-2 receptor monoclonal antibodies and renal graft loss (2017) (0)
Screening and outcome measures (2016) (0)
Carer information sheet (2016) (0)
Carer consent form (2016) (0)
Association between reproducible flow cytometric methodology for measuring multidrug resistance and remission rates in AML (1998) (0)
cytometry. IV. CD34 overexpression in acute myelogenous leukemia Leukemia-associated changes identified by quantitative flow (2011) (0)
reliability and utility for identifying disease subtypes Bone marrow pathology in essential thrombocythemia: interobserver (2013) (0)
Does centre size influence outcome in the treatment of AML in adult patients under 60 years? The MRC AML trial experience [Abstract] (2003) (0)
Patient baseline data at randomisation (2016) (0)
Hoehn and Yahr stages (2016) (0)
P1.157 Sensitivity to change of quality of life rating scales used in the PD MED trial (2009) (0)
Initial interview log (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Keith Wheatley?

Keith Wheatley is affiliated with the following schools:

Keith Wheatley's Academic­Influence.com Rankings

Keith Wheatley's Degrees

Similar Degrees You Can Earn

Why Is Keith Wheatley Influential?

Keith Wheatley's Published Works

Published Works

What Schools Are Affiliated With Keith Wheatley?

Keith Wheatley's AcademicInfluence.com Rankings